The initiative aims to increase biomarker testing rates in communities most impacted by lung cancer disparities. The novel B7-H3–targeting antibody-drug conjugate has a novel payload. More than half of patients in the study had psychological distress as well as elevated serum cortisol levels. Study investigators say the results support further study of the bispecific T-cell engager in previously treated SCLC. The study showed that patients with certain types of insurance had significantly shorter overall survival. Dr. Rami Manochakian and The Oncology Brothers discusses treatment for SCLC, which is evolving at a rapid pace. Dr. Spigel discusses the implications of ADRIATIC at the 2024 American Society of Clinical Oncology Annual Meeting. The median investigator-assessed PFS was 5.7 months in patients who received bevacizumab plus ACE. The ADRIATIC results were presented during a plenary session at the 2024 American Society of Clinical Oncology Meeting. Researchers aimed to address the limited data on combining a PD-L1 inhibitor with chemotherapy in older adults. Exposures to substances such as Agent Orange are "not currently addressed in prevailing risk models." The treatment is the first and only bispecific T-cell engager therapy for advanced SCLC. Global clinical trials are scheduled to begin after IND approval is received for phase 2 trials in the US and Europe. The primary end point of the RESILIENT trial was OS. The timing of chemotherapy given to patients with SCLC does not have a statistically significant impact on OS. The timing of chemotherapy given to patients with SCLC does not have a statistically significant effect on OS. Chemotherapy-induced myelosuppression among patients with extensive-stage SCLC is poorly understood. The DeLLphi-301 study that evaluated patients with advanced SCLC. Lurbinectedin monotherapy is currently being studied in Jazz EMERGE 402 study in patients with metastatic SCLC. Researchers from the US and Italy have identified a biomarker that can distinguish between SCLC and SCC.